Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Organogenesis Holdings Inc (ORGO)

Organogenesis Holdings Inc (ORGO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Organogenesis: Q2 Earnings Snapshot AP - Thu Aug 6, 4:22PM CDT

Organogenesis: Q2 Earnings Snapshot

ORGO : 1.8100 (-4.23%)
Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results GlobeNewswire - Thu Aug 6, 3:05PM CDT

CANTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development,...

ORGO : 1.8100 (-4.23%)
Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers GlobeNewswire - Mon Jul 27, 3:05PM CDT

CANTON, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical...

ORGO : 1.8100 (-4.23%)
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026 GlobeNewswire - Thu Jul 9, 6:30AM CDT

CANTON, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development,...

ORGO : 1.8100 (-4.23%)
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis GlobeNewswire - Mon Jul 6, 3:05PM CDT

CANTON, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical...

ORGO : 1.8100 (-4.23%)
MarketBeat.com
Organogenesis Q1 Earnings Call Highlights MarketBeat - Fri May 8, 7:07AM CDT

Organogenesis (NASDAQ:ORGO) reported a sharp year-over-year revenue decline in the first quarter of 2026, with executives pointing to significant disruption in the skin substitute market following Medicare...

ORGO : 1.8100 (-4.23%)
Organogenesis: Q1 Earnings Snapshot AP - Thu May 7, 4:49PM CDT

Organogenesis: Q1 Earnings Snapshot

ORGO : 1.8100 (-4.23%)
Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results GlobeNewswire - Thu May 7, 3:05PM CDT

CANTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development,...

ORGO : 1.8100 (-4.23%)
Organogenesis Completes Rolling Submission of Biologics License Application for ReNu® GlobeNewswire - Tue Apr 28, 3:30PM CDT

CANTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of...

ORGO : 1.8100 (-4.23%)
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM GlobeNewswire - Mon Apr 6, 6:02PM CDT

Statistically significant (p

ORGO : 1.8100 (-4.23%)

Barchart Exclusives

Why Wall Street Isn't Buying Super Micro's $60 Billion Backlog Quite Yet Barchart - 37 minutes ago
While the record backlog and strong demand are likely to translate into sustainable revenue growth, Wall Street analysts aren't bullish on SMCI stock. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.